Screener
Krystal Biotech, Inc. KRYS Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Maturities of investments | 103,598 | 88,806 |
| Net cash (used in) investing activities | (63,583) | (54,769) |
| Financing Activities | ||
| Proceeds from exercise of stock options | 6,501 | 1,462 |
| Taxes paid for employee tax withholding related to restricted stock units | (16,960) | (12,116) |
| Taxes paid related to settlement of restricted stock awards | — | (1,812) |
| Net cash (used in) financing activities | (10,459) | (12,466) |
| Effect of exchange rate changes on cash and cash equivalents | (1,331) | 171 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s stock issuance proceeds?
- Krystal Biotech, Inc. (KRYS) reported stock issuance proceeds of $6.5M in Q1 2026.
- How has Krystal Biotech, Inc.'s stock issuance proceeds changed year-over-year?
- Krystal Biotech, Inc.'s stock issuance proceeds increased by 344.7% year-over-year, from $1.46M to $6.5M.
- What is the long-term trend for Krystal Biotech, Inc.'s stock issuance proceeds?
- Over 3 years (2021 to 2025), Krystal Biotech, Inc.'s stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $355.84M to $0.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Krystal Biotech, Inc.'s stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude